(Albany , US) , September 10 , 2026 – DelveInsight’s “Sciatica Treatment Market Insights, Epidemiology, and Market Forecast – 2032” report offers an in-depth understanding of sciatica, along with historical and forecasted epidemiology and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan, covering 2019 to 2032.
To know in detail about the Sciatica market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Sciatica Market Forecast
Some of the key facts of the Sciatica Market Report:
The Sciatica Treatment Market across the 7MM is projected to expand at a notable CAGR through 2032, supported by an active late-stage pipeline of novel therapies.
There is currently no FDA-approved drug specifically indicated for sciatica; available medications (NSAIDs, corticosteroids, muscle relaxants, anticonvulsants, opioids, antidepressants) are used largely off-label to manage pain and inflammation.
SEMDEXA (SP-102), developed by Scilex Pharmaceuticals, is a non-opioid injectable corticosteroid gel formulation targeting lumbosacral radicular pain; it received FDA Fast Track designation in 2021 and is currently in pivotal Phase III trials in the US.
STX-015, an alpha-2 adrenergic receptor agonist developed by Sollis Therapeutics, is being evaluated in Phase III trials for low back and leg pain associated with sciatica.
SB0101, being developed by Sinfonia Biotherapeutics, is currently in Phase II development.
The COVID-19 pandemic negatively impacted the Sciatica Treatment Market, as decreased hospital visits led to fewer diagnoses and delayed treatment initiation.
The United States accounted for the largest share of the 7MM Sciatica market in 2022, attributed to high disease prevalence and higher treatment costs, a trend expected to continue with the potential early entry of new therapies.
As per Clarke et al. (2016), roughly 54.5% of US adults report a musculoskeletal pain disorder (a category that includes sciatica, lower back pain, neck pain, and joint pain); based on National Health Interview Survey (2012) estimates, approximately 12 million people in the US are affected by sciatica.
According to Koes et al. (2007), a herniated spinal disc pressing on a lumbar or sacral nerve root is responsible for roughly 90% of sciatica cases.
Davis et al. (2022) found no clear gender predominance in sciatica, with a lifetime incidence estimated between 10% and 15%.
Matsudaira et al. (2013), in a Japanese occupational cohort study, reported that 18.4% of eligible participants experienced a new sciatica episode.
DelveInsight’s analysts engaged with more than 50 Key Opinion Leaders (KOLs) globally, conducting in-depth interviews with over 15 KOLs across the 7MM, including experts from Nantes Université (France) and the Department of Neurological Surgery at Duke University Medical Center (US).
Key Sciatica Companies: Scilex Pharmaceuticals, Sollis Therapeutics, SpineThera, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon Life Science, Teijin America, and others.
Key Sciatica Therapies: SEMDEXA (SP-102), STX-015, SB0101, and others.
Sciatica Overview
Sciatica refers to pain that radiates along the path of the sciatic nerve, extending from the lower back through the hips and buttocks and down each leg, typically affecting only one side of the body. It most commonly results from compression of the L4, L5, or S1 nerve roots, and less frequently from irritation of the S2/S3 nerve roots or the sciatic nerve itself. Common contributing factors include age-related spinal degeneration, obesity, occupations involving heavy lifting, prolonged sitting, and diabetes, with spinal disc herniation being the leading cause. Other potential causes include spondylolisthesis, musculoskeletal pain disorders, piriformis syndrome, pelvic tumors, and pregnancy. Sciatica can present as acute, chronic, alternating, or bilateral, and is typically diagnosed through physical examination combined with a review of symptom history and, where needed, imaging.
Get a Free sample for the Sciatica Market Report: https://www.delveinsight.com/report-store/sciatica-market
Sciatica Epidemiology
The epidemiology section provides insights into historical, current, and forecasted trends across the seven major markets (7MM) from 2019 to 2032, drawing on published studies and the perspectives of key opinion leaders to explain observed and projected trends, along with a detailed view of the diagnosed patient pool.
Sciatica Epidemiology Segmentation: The Sciatica market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Sciatica Diagnosed Prevalent Cases
Sciatica Age-Specific Diagnosed Prevalent Cases
Sciatica Comorbidities Associated with Diagnosed Prevalent Cases
Download the report to understand which factors are driving Sciatica epidemiology trends @ Sciatica Epidemiology Forecast
Sciatica Market
The dynamics of the Sciatica market are anticipated to shift over the coming years due to the expected entry of new therapies during the forecast period (2019–2032).
“The current Sciatica treatment landscape lacks disease-modifying therapies and standardized treatment guidelines; while symptomatic treatments are widely used, they offer only mild to moderate pain relief, underscoring a significant unmet need in the market.”
Sciatica Therapies and Key Companies
SEMDEXA (SP-102) — Glucocorticoid receptor agonist, administered via epidural injection — Scilex Pharmaceuticals — Phase III
STX-015 — Alpha-2 adrenergic receptor agonist — Sollis Therapeutics — Phase III
SB0101 — Sinfonia Biotherapeutics — Phase II
To know more about Sciatica treatment, visit @ Sciatica Medications
Sciatica Market Drivers
Rising Sciatica Incidence and Growing Geriatric Population
Increasing Prevalence of Herniated Discs and Degenerative Disc Disease
Advancements in Diagnostic Techniques
Development of Novel, Non-Opioid Therapies
Improved Healthcare Access
Greater Disease Awareness Among Patients and Physicians
Sciatica Market Barriers
Absence of FDA-Approved, Disease-Specific Therapies
Lack of Standardized Treatment Guidelines
Reliance on Off-Label Symptomatic Treatments
High Costs and Limited Access to Advanced Therapies
Inconsistent Care Due to Varying Physician Approaches
Lingering Impact of Reduced Hospital Visits Post-COVID-19
Scope of the Sciatica Market Report
Study Period: 2019–2032
Forecast Period: 2023–2032
Coverage: 7MM
Key Sciatica Companies: Scilex Pharmaceuticals, Sollis Therapeutics, SpineThera, Sinfonia Biotherapeutics, Seikagaku Corporation, Kolon Life Science, Teijin America, and others
Key Sciatica Therapies: SEMDEXA (SP-102), STX-015, SB0101, and others
Sciatica Therapeutic Assessment: Current marketed therapies and emerging Sciatica therapies
Sciatica Market Dynamics: Market drivers and market barriers
Competitive Intelligence Analysis: SWOT analysis, Market entry strategies
Sciatica Unmet Needs, KOL’s views, Analyst’s views, Sciatica Market Access and Reimbursement
Table of Content
Key Insights
Report Introduction
Sciatica Market Overview at a Glance
Key Events
Sciatica Epidemiology and Market Methodology
Executive Summary of Sciatica
Disease Background and Overview
Sciatica Epidemiology and Patient Population
Sciatica Marketed Therapies
Emerging Sciatica Therapies
Sciatica Patient Journey
Sciatica: 7MM Analysis
The United States: Sciatica Market Size
The EU4 and the UK Sciatica Market Size
Japan Sciatica Market Size
Sciatica Market Access and Reimbursement
Unmet Needs
SWOT Analysis
KOL Views
Appendix
DelveInsight’s Capabilities
Disclaimer
About DelveInsight’s
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, benefiting market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kanishk KumarEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/sciatica-market
